Strata Critical Medical, Inc. (SRTA)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$5.32-0.93%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
QuarterlyIQ Insights · SRTA
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -46.8% |
| Our one-year growth estimate | diamond | 20.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 256 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 66.8 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 27 industry peers · Company calendar date is not available
SRTA — earnings in line
Dated 2026-08-04
Results of Operations and Financial Condition. On August 4, 2026, Strata Critical Medical, Inc. (“Strata”) issued a press release announcing its financial results for the second quarter ended June 30, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein. This information is intended to be furnished under
Why it matters: If companies like Lilly or Johnson & Johnson do well, it helps Strata.
Supportive ifPeer companies report strong revenue growth or improved outlooks.
Worry ifPeers are seeing lower revenues or bad outlooks.
Why it matters: Meeting or exceeding this number shows progress toward the 2026 revenue target of $260-275M.
Supportive ifQ2 revenue reported at or above $67.4M.
Worry ifQ2 revenue reported below $67.4M.
Why it matters: This date is important for checking financial performance and future plans.
Watch forEarnings report shows strong results and raises guidance.
Also watch forEarnings report shows weak results and lowers guidance.
Why it matters: Hitting this revenue target shows strong growth. It also shows good management.
Supportive ifTotal revenue reaches or exceeds $75 million in Q3 2026.
Worry ifTotal revenue falls below $70 million in Q3 2026.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$197 on $10,000 · ±2.0% | How much price usually moves either way. |
| Bad day | $509 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,221 loss on $10,000 · 32.2% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Hitting this target shows the company is keeping costs low while making more money.
Supportive ifAdjusted EBITDA of $29 million or higher in Q2.
Worry ifAdjusted EBITDA falls below $25 million in Q2.
Why it matters: This update will show if Strata can meet its cash flow target for 2026.
Watch forManagement raises free cash flow guidance to $22M or higher.
Also watch forManagement lowers free cash flow guidance below $15M.
Why it matters: A drop could signal a slowdown in the healthcare sector, impacting Strata's performance.
Worry ifSector revenue growth reported below its median.
Less concerning ifSector revenue growth remains above its median.
Why it matters: Positive cash flow means the company is making cash to help it grow.
Supportive ifCash flow from operations exceeds $4 million in Q2.
Worry ifCash flow from operations is below $3 million in Q2.
Why it matters: Health Care sector growth is slowing. If revenue growth re-accelerates, it could help Strata's outlook.
Supportive ifHealth Care sector revenue growth is speeding up again. It is moving toward 10% or higher.
Worry ifSector revenue growth is slowing down. It is now below 10%.
Why it matters: This cash flow is important for funding growth and operations, showing financial strength.
Supportive ifFree cash flow reported in the range of $15-22M.
Worry ifFree cash flow reported below $15M.
Why it matters: Achieving this range is key for financial health and aligns with management's goals.
Supportive ifAdjusted EBITDA was between $29M and $33M.
Worry ifAdjusted EBITDA was under $29M.
Why it matters: Good acquisitions can boost growth and improve market position in the transplant field.
Supportive ifLook for news of at least one more acquisition by Q3.
Worry ifNo acquisitions announced by Q3.
Why it matters: Slower growth may show problems in keeping up after strong Q2 results.
Worry ifQ3 revenue growth below 7% sequentially from Q2's $72.5 million.
Less concerning ifQ3 revenue growth above 7% sequentially from Q2's $72.5 million.
Why it matters: A drop could mean higher costs or problems, which can hurt profits.
Worry ifAdjusted EBITDA margin drops below 10% in Q3 2026.
Less concerning ifAdjusted EBITDA margin stays above 10% in Q3 2026.
Why it matters: Lower cash flow could impact future investments and growth plans.
Worry ifFree cash flow in Q3 falls below $2 million.
Less concerning ifFree cash flow in Q3 exceeds $2 million.
Why it matters: A slowdown may show issues in the clinical services growth plan.
Worry ifClinical revenue growth drops below 15% sequentially from Q2's $24.3 million.
Less concerning ifClinical revenue growth is over 15% from Q2's $24.3 million.